| Recent increases in the incidence of endometrial carcinoma represent a significant risk to women's health.Treatment options are limited and prognosis is poor for patients with metastatic or recurring endometrial carcinoma.Therefore,new therapeutic regimens such as immunotherapy are actively being evaluated for treatment of advanced endometrial carcinoma.Although there have been no large-scale clinical trials of PD-1/PD-L1 blockade therapy for treatment of endometrial carcinoma,recent small-sample clinical trials have suggested that this strategy may be beneficial.We found that ?-glutamyl cyclotransferase(GGCT)was significantly up-regulated in endometrial carcinoma tissues and cells,which suggested that it may be a potential target for treatment of endometrial carcinoma.Furthermore,the impact of GGCT on proliferation,migration,and invasion of endometrial carcinoma has been demonstrated in vitro and in vivo using GGCT silencing and overexpression techniques.We also found that GGCT knockdown resulted in decreased PD-L1 expression,which suggested that dramatic changes in GGCT levels may be involved in the activation of the PD-1/PD-L1 signal pathway of endometrial carcinoma.In conclusion,our study showed that GGCT contributed to malignant progression and upregulation of PD-L1 expression of endometrial carcinoma,and may be a potential target for treatment of endometrial carcinoma. |
PDF Full Text Request